Challenges of designing hepatic encephalopathy treatment trials
Madhusudhan R. Sanaka, Janus P. Ong, Kevin D. Mullen – 30 December 2003 – Background/Aims: The efficacy and safety of rifaximin in comparison with lactitol in the treatment of hepatic encephalopathy was assessed in a prospective randomized, double‐blind, double‐dummy, controlled trial. Methods: A total of 103 patients with grade I‐III acute hepatic encephalopathy were randomized to receive rifaximin (50 patients, 1200 mg/day) or lactitol (53 patients, 60 g/day) for 5‐10 days.